Status:

COMPLETED

Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Children

Lead Sponsor:

ZARS Pharma Inc.

Conditions:

Pain

Eligibility:

All Genders

Up to 17 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to evaluate the safety of one treatment of S-Caine™ Peel (skin numbing cream) applied on healthy skin before a painful dermatologic procedure in children. This study will ...

Detailed Description

The practice of dermatology is seeing a rise in the number of surgical and laser procedures as technological advances have expanded the number of conditions amenable to these evolving therapies. Skin ...

Eligibility Criteria

Inclusion

  • Patient is 0 through 17 years of age.
  • Patient requires a minor or major dermal procedure.
  • Patient's legal guardian is able to read and understand a written informed consent and has signed and dated a written informed consent. The patient must provide assent whenever possible.

Exclusion

  • Patient has known allergies, contraindications or sensitivities to lidocaine, tetracaine, or other local anesthetics of the amide or ester type or to any components of the test materials.
  • Patient has known active atopic dermatitis at the designated treatment site.
  • Patient has damaged, denuded or broken skin at the designated treatment site.
  • Patient is pregnant or breastfeeding.
  • Patient has participated in an investigational study or clinical trial of an unapproved drug within the previous 30 days.
  • Patient was born prematurely (less than 38 weeks).
  • Patient has enrolled in any previous study involving S-Caine Peel.

Key Trial Info

Start Date :

April 1 2005

Trial Type :

INTERVENTIONAL

End Date :

May 1 2005

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT00107822

Start Date

April 1 2005

End Date

May 1 2005

Last Update

October 6 2005

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

International Dermatology Research, Inc.

Miami, Florida, United States, 33174

2

Jacobi Medical Center

The Bronx, New York, United States, 10461

3

Tennessee Clinical Research Center

Nashville, Tennessee, United States, 37215